DexCom, headquartered in San Diego, develops glucose monitoring systems for diabetes management, employing 9,600 people since its IPO in 2005. Its products include the Dexcom G6 and G7 continuous glucose monitoring systems.
Kevin R Sayer sold 32,498 shares of DXCM on 12 March at $70.38 per share, worth a total of $2.3M. They now own 372,029 DXCM shares, or a 8% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
